Moneycontrol
HomeNewsBusinessStartupMakeMyTrip taps offline agents to bring back business, post-COVID-19
Trending Topics

MakeMyTrip taps offline agents to bring back business, post-COVID-19

Travel agency launches a dedicated platform called myPartner. Since travel agents have a pan-India base, very loyal customer base and a deep understanding of the industry, they play a crucial role in the business, says the firm.

August 25, 2020 / 14:13 IST
Story continues below Advertisement
Representative image

Nasdaq-listed online travel agency MakeMyTrip is partnering with offline travel agents to woo travellers back, with the launch of a dedicated platform called myPartner, post COVID-19.

The partnership will be for hotel inventory on the platform. MakeMyTrip claims to have over 60,000 accommodation properties in India and 5,00,000 outside the country listed on its site.

Story continues below Advertisement

The company, which is far from its pre-Covid volumes, is targeting at least 50-60 percent recovery across the overall activities it offers on its site by the end of the financial year.

“We do not have a hard target. The idea is to take a long-term view. If we get to 50-60 percent by the end of the year, we would be lucky,” Rajesh Magow, Group CEO, MakeMyTrip, told reporters over a video conference.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show